Skip to content
  • About NanoEcho
  • Method
  • Clinical Studies
  • Market
  • Governance
    • Management and board
    • General meetings
    • Corporate Governance
    • Nominating committee
  • Investor Relations
    • Reports
    • Owners
    • Financial calendar
    • Prospectus/Offer
    • The Share
    • Certified Adviser
    • References
  • News & Media
    • Press Releases
    • News
    • Investor Letters
    • Subscribe
    • Media Bank
    • Presentations
    • NanoEcho in the Media
  • Contact
    • Contact
    • Career
  • About NanoEcho
  • Method
  • Clinical Studies
  • Market
  • Governance
    • Management and board
    • General meetings
    • Corporate Governance
    • Nominating committee
  • Investor Relations
    • Reports
    • Owners
    • Financial calendar
    • Prospectus/Offer
    • The Share
    • Certified Adviser
    • References
  • News & Media
    • Press Releases
    • News
    • Investor Letters
    • Subscribe
    • Media Bank
    • Presentations
    • NanoEcho in the Media
  • Contact
    • Contact
    • Career
  • SV

News Tag: mfn-cus-sahlgrenskauniversitetssjukhuset

NanoEcho’s innovative method, with its high precision, aims to facilitate the differentiation between diseased and healthy tissue and at the same time determine a more precise localization of cancerous tissue. The goal is to provide a more reliable diagnosis of, for example cancer diseases, that has the potential to contribute to cost-effectiveness in the health care.

Not For Sale – For Clinical Investigation Use Only – EU Trial No.: 2024-515335-29-00

NanoEcho AB
Scheelevägen 19,
223 63 Lund
info@nanoecho.se

Facebook Linkedin Youtube Envelope
Copyright 2024 NanoEcho © All Rights Reserved.
Privacy policy